Source : https://pubmed.ncbi.nlm.nih.gov/42149072/
Clinicians should consider monitoring serum sodium in patients receiving GLP-1 receptor agonists, particularly when used alongside medications affecting sodium balance, such as thiazide-like diuretic agents.
Case suggests a potential association between tirzepatide and recurrent hyponatremia, particularly with concomitant chlorthalidone use, highlighting the importance of serum sodium monitoring during GLP-1 receptor agonist therapy.
Source : https://pubmed.ncbi.nlm.nih.gov/40932169/
Leptin, a key adipokine regulating energy homeostasis, has been extensively studied for its potential in the management of obesity. However, its therapeutic efficacy is often limited due to leptin resistance....
This review examines leptin biology and mechanisms of leptin resistance in obesity, highlighting impaired signaling pathways, inflammation, and hyperleptinemia while discussing emerging strategies including leptin sensitization, combination therapies, and MC4R agonists.
Source : https://pubmed.ncbi.nlm.nih.gov/40568283/
The global rise in obesity has intersected with increasing breast cancer incidence, generating a critical need to understand how excess adiposity affects diagnostic accuracy, treatment delivery, and patient outcomes. Although...
This systematic review highlights how obesity complicates breast cancer care through diagnostic delays, surgical complications, altered drug metabolism, treatment toxicity, and multimorbidity, emphasizing the need for personalized obesity-specific management strategies.
Source : https://pubmed.ncbi.nlm.nih.gov/41405359/
Effect of CLMs on AD is biologically plausible but clinically unproven. Signals of concern are most consistent for 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and Niemann-Pick C1-Like 1 (NPC1L1) inhibition, whereas...
Cholesterol-lowering drugs may influence atopic dermatitis via skin barrier effects, but evidence is inconclusive; statins/NPC1L1 inhibitors show concern, PCSK9 inhibitors may protect; prioritize cardiovascular benefits while monitoring dermatitis.
Most patients prescribed semaglutide lacked comprehensive pre-treatment screening, with only 1.8% fully assessed. Missing evaluations—especially for thyroid, pancreatic, and ocular risks—may increase the likelihood of severe complications despite known safety concerns.